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Background: In the treatment of major depressive disorder (MDD), it is not fully understood how in-
dividual symptoms improve over time (trajectory) in remitters. This study compared symptom im-
provement trajectories, as measured with the 17-item Hamilton Depression Rating Scale (HAM-D17), in
remitters and nonremitters.
Methods: This analysis is based on 10 placebo-controlled, randomized, double-blind trials of duloxetine
(40–60 mg/day) for treatment of MDD from baseline up to week 8. Remission was deﬁned as a HAM-D17
total score r7 at week 8 (last observation carried forward). Trajectories of HAM-D17 items were as-
sessed by mixed model repeated measures analysis for treatment and remitter-nonremitter comparisons.
Grouping of the trajectories was performed by factor analysis. Predictor analysis using HAM-D17 items
was conducted by logistic regression.
Results: There were 1555 patients in the duloxetine group (489 [31.4%] remitters) and 1206 patients in
the placebo group (290 [24.0%] remitters; Po .0001). For most items, the difference in trajectories be-
tween remitters and nonremitters appeared at early time points and increased over time. Treatment
response trajectories were very similar for duloxetine and placebo remitters, while duloxetine non-
remitters improved more than placebo nonremitters. For duloxetine remitters, we found 3 trajectory
groups of HAM-D17 items. The predictor analysis showed that improvement in 6 individual items at
week 1 or 2 was signiﬁcantly associated with remission at week 8.
Limitations: Generalizability of these results may be limited by the relatively short observation period
used to deﬁne remission.
Conclusions: Early monitoring of some symptoms of depression may prove useful in guiding treatment
decisions.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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kuoka).1. Introduction
For recovery from major depressive disorder (MDD), remission
is a critical treatment goal. Failure to reach remission leads to
higher probability of relapse (Pintor et al., 2003). Reaching re-
mission is, moreover, needed to recover psychosocial functioning
comparable to nondepressed people (Miller et al., 1998).
However, remission is not readily achieved. Trivedi et al.
(2006), reporting results from the Sequenced Treatment Alter-
natives to Relieve Depression (STAR*D) study, found that only
27.5% of patients treated with a selective serotonin reuptake in-
hibitor (SSRI) reached remission in 14 weeks when assessed withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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characteristics of patients with MDD are associated with remis-
sion. For example, in the STAR*D study, gender, employment sta-
tus, education history, baseline function, and quality of life were
shown to affect remission rates (Trivedi et al., 2006).
Another question regarding remission is whether or not early
symptom improvement is predictive of remission. Lack of early (at
2 weeks) response to ﬂuoxetine has been shown to predict a poor
outcome at 8 weeks (Nierenberg et al., 1995, 2000). Furthermore,
early improvement in the ﬁrst 2 weeks as measured by Hamilton
Depression Rating Scale (HAM-D) total score or subscale scores
may predict later remission (Henkel et al., 2009; Katz et al., 2009;
Szegedi et al., 2009). However, it is not clear whether some HAM-
D items are better predictors than others.
Depressive disorders show many different types of symptoms.
Accordingly, it is interesting to compare the degree of symptom
improvement over time (trajectory) in patients who eventually
reach remission (remitters) with those who do not (nonremitters).
For example, responses on some items could improve faster or
better than others in remitters, but not in nonremitters. Trajec-
tories of individual symptoms in remitters and nonremitters were
examined by secondary analysis of the STAR*D trial data (Sakurai
et al., 2013). In that study, patients were treated with citalopram,
and symptoms were evaluated using the16-item Quick Inventory
of Depressive Symptomatology, Self-Report (QIDS-SR16) and the
16-item Quick Inventory of Depressive Symptomatology, Clinician
Rating (QIDS-C16) versions. Analysis of trajectories of symptoms
revealed substantial separation between remitters and non-
remitters for almost all symptoms. However, the differences be-
tween trajectories of remitters and nonremitters when assessed
with the HAM-D, a more broadly used depression scale for clinical
trials, are not known. Moreover, trajectories may depend on the
antidepressant used, as each of them has its own pharmacological
proﬁle.
Duloxetine (DLX) is a potent inhibitor of serotonin (5-hydro-
xytryptamine) and norepinephrine reuptake and is relatively ba-
lanced in its binding afﬁnity for serotonin and norepinephrine
transporter sites (Bymaster et al., 2003; Wong and Bymaster,
2002). Acute administration of DLX increases extracellular mono-
amine levels (Karpa et al., 2002), thereby enhancing mono-
aminergic tone. DLX has demonstrated efﬁcacy in the acute
treatment of MDD in multiple randomized, double-blind, placebo
(PLA)-controlled trials (Detke et al., 2002; Goldstein et al., 2002;
Nemeroff et al., 2002). Moreover, a recent comparison of DLX and
SSRIs suggested DLX has good efﬁcacy for the core symptoms of
MDD (Harada et al., 2015). However, despite the large amount of
data supporting the efﬁcacy of DLX as an antidepressant, it is not
yet known precisely how DLX-treated patients experience im-
provement of symptoms. In addition, given the fact that a sub-
stantial number of patients experience remission even with PLA, it
is still unknown whether there are any differences in the trajec-
tories of improvement of individual symptoms between remitters
treated with PLA and those treated with antidepressants.
In this analysis of PLA-controlled trials of DLX, we examined
the trajectories of depression symptoms (items on the 17-item
Hamilton Scale of Depression [HAM-D17]) in remitters, compared
with nonremitters, treated with DLX. Furthermore, we examined
these trajectories in PLA-treated patients, remitters versus non-
remitters. A factor analysis (principal component analysis) was
performed to determine if there are patterns of symptom im-
provement in DLX and remitters. Finally, a predictor analysis was
utilized to assess if early improvement on any HAM-D17 items
predict remission at endpoint.2. Methods
2.1. Data sources
The data used in the present post-hoc analysis (Supplementary
Table 1) were extracted from the integrated database of DLX
clinical trials, which includes all clinical trials for MDD with DLX
conducted by Eli Lilly and Co. The number of clinical trials included
in the database is 39. This database allowed us to conduct a pa-
tient-level analysis. From the database, we included all of the trials
which met the following inclusion criteria: acute (at least 6 weeks
in duration), PLA-controlled, randomized, double-blind trials of
DLX for the treatment of MDD; at least 1 DLX arm of Z40 mg/day
and r60 mg/day; and use of the 17-, 21-, or 24-item version of
the Hamilton Depression Rating Scale (HAM-D17, HAM-D21, and
HAM-D24, respectively). We excluded relapse-prevention and
nonresponder trials.
As a result of screening, 10 trials met all criteria; they were used
in the present post-hoc analysis (Supplementary Table 1). For the
DLX group, only patients treated with Z40 and r60 mg/day DLX
were included in this analysis since this dose range has been
conﬁrmed as effective in the treatment of MDD and is commonly
used globally (Ball et al., 2013; Cowen et al., 2005). Only data from
the acute treatment phases of the studies throughout week 8 (up
to day 70) were included in the analyses. No maintenance treat-
ment phases were included in the analyses.
For the individual trials included in this analysis, patients were
required to meet several inclusion criteria, including meeting the
criteria for MDD, as deﬁned by the Diagnostic and Statistical
Manual-IV-Text Revision (DSM-IV-TR) (American Psychiatric As-
sociation, 2000), and were required to sign an informed consent
document. Exclusion criteria typically included having any current
Axis I disorder other than MDD, having a current or previous di-
agnosis of bipolar disorder or any psychotic disorder, having any
organic mental disorder, dementia, or mental retardation, being at
serious suicidal risk (in the judgment of the investigator), and
having a recent history of substance abuse or dependence. Study
protocols permitted minimum anxiolytic use by the patients.
The protocols for the individual studies were reviewed and
approved by the applicable organizational ethical review boards.
The studies were conducted in accordance with the ethical prin-
ciples of the Declaration of Helsinki, Good Clinical Practice, and
applicable laws and regulations.
The clinical trials included in this analysis were registered at
ClinicalTrials.gov. Study Identiﬁers are as follows: NCT00036335;
NCT00073411; NCT00406848 and NCT00536471. Studies HMAQa,
HMAQb, HMATa, HMATb, HMBHa and HMBHb predate the regis-
tration requirement.
2.2. Time frame of analysis
The time frame of data collection was restricted to the acute
phase of the clinical trial, beginning with the baseline visit and
ending with the endpoint visit of the acute phase or 70 days after
baseline, whichever occurred ﬁrst. The time frame start deﬁnition
excluded any “lead-in phase,” and the deﬁnition of time frame end
excluded the data in any open-label trial extension. Analysed data
included baseline (week 0), week 1 (day 7, range 1–10 days
postbaseline), week 2 (day 14, range 11–21 days postbaseline),
week 4 (day 28, range 22–35 days postbaseline), and week 8 (day
56, range 43–70 days postbaseline). If there were more than 2 data
points within the allowance range of a speciﬁc time point for a
patient, the data nearest the date of the speciﬁc time point was
used. If there were more than 2 data points at the nearest date of
the speciﬁc time point for a patient, the average of these data
points was used for the speciﬁc time point for that patient.
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Based on intent-to-treat principles, all randomized patients
assigned to DLX (40 to 60 mg/day) or placebo with baseline and at
least 1 postbaseline HAM-D assessment were included in the
analyses. A last observation carried forward (LOCF) approach was
used to determine remitter/nonremitter status for patients. Re-
mission was deﬁned as a HAM-D17 total score r7 at week 8 or
endpoint.
Trajectories (assessment of efﬁcacy over time) were calculated
and graphed for individual items, the HAM-D17 total score (Ha-
milton, 1960), and subscale scores. Subscales included in the
analysis were as follows: Bech (HAM-D17 items 1, 2, 7, 8, 10, and
13) (Bech et al., 1975), Maier (HAM-D17 items 1, 2, 7, 8, 9, and 10)
(Maier and Philipp, 1985), Anxiety/somatization (HAM-D17 items
10, 11, 12, 13, 15, and 17), Retardation (HAM-D17 items 1, 7, 8, and
14), and Sleep (HAM-D17 items 4, 5, and 6) (Cleary and Guy,
1977).
A mixed model repeated measures (MMRM) analysis was used for
treatment and remitter status comparisons. In particular, the model
was response¼groupþtreatmentþweekþgroup*weekþtreatment*
weekþgroup*treatmentþgroup*treatment*weekþpatient (treatment:
DLX or PLA; group: remitter or nonremitter; week: 0, 1, 2, 4, or 8; with
patient¼random effect. For sensitivity analysis, the same MMRM
method on restricted population with the complete dataset (available
case¼AC) was applied. Here, AC means patients data with all baseline
and all postbaseline (weeks 0,1, 2, 4, and 8) for all HAM-D items. Hence,
remitters and nonremitters were deﬁned without LOCF.
To group individual HAM-D17 items in terms of a similar im-
provement pattern over time, factor analysis (principal component
analysis) with a Varimax rotation was applied to the individual
HAM-D17 items at each time point. Data from DLX and PLA re-
mitters were used. First, for each time point, change from baseline
divided by the item maximum value was calculated for each of 17
items for each subject, and factor analysis was applied. The ex-
traction process was terminated when the last eigenvalue was less
than 1.00. Second, given the factors at each time point, we iden-
tiﬁed groups of HAM-D17 items which showed the same pattern
of factor categorization for all time points (weeks 1, 2, 4, and 8).
See more details in Supplementary Methods.
A predictor analysis was also performed to investigate to what
extent early improvement of each HAM-D17 item predicts remis-
sion. For that analysis, a logistic regression, in which response
equaled remitter versus nonremitter, was used to compare change
on the HAM-D17 total score, subscale scores, and individual item
scores from week 0 to week 1 and week 0 to week 2. For example,
DLX remitters with HAM-D17 item 1 week 0 to week 1 change
logistic regression model was Logit (Response)¼(-) item 1 Change
(week 1–week 0).
We further used stepwise and backward algorithms for model
selection based on all HAM-D17 items. See more details in Sup-
plementary Methods. Based on selected models, Receiver Oper-
ating Characteristic (ROC) curves and Area Under the Curve (AUC)
were created using sensitivity and speciﬁcity to check predict-
ability. AUC can be used as a summary measure of how well the
selected models predict remitter/nonremitter status.
All statistical analyses were conducted using SAS v 9.2 (SAS
Institute, Inc., Cary, NC, USA). All statistical tests were conducted
at the .05 signiﬁcance level (2-sided), with no adjustments for
multiple comparisons. ROC curves were created with SAS v 9.2;
other ﬁgures were created with R 3.1.0 for Windows (64 bit
version).3. Results
3.1. Patient baseline characteristics and disposition
From 10 PLA-controlled studies of DLX, a total of 2761 patients
were included in the present analysis. There were 1555 patients in
the DLX group, of which 489 (31.4%) were remitters; there were
1206 patients in the PLA group, of which 290 (24.0%) were re-
mitters (Po .0001). Groups (DLX versus PLA) were well balanced
in terms of their baseline demographics and disease characteristics
(Table 1).
Patient disposition is presented in Table 2. DLX remitters,
compared to DLX nonremitters, had a lower early discontinuation
rate, primarily due to a lower frequency of discontinuations due to
adverse events (AEs) in this group. PLA remitters also had a lower
early discontinuation rate than PLA nonremitters, mostly because
fewer remitters discontinued due to lack of efﬁcacy. Overall, the
rate of early discontinuation was lower in DLX-treated patients,
compared to PLA-treated patients. For DLX-treated patients, the
most common reason for early discontinuation was AEs, both for
remitters and nonremitters. For PLA-treated patients, the most
common reason for early discontinuation for remitters was “pa-
tient decision,” whereas for nonremitters the most common rea-
son for early discontinuation was “lack of efﬁcacy”.
3.2. Trajectories of HAM-D17 items and subscales in duloxetine-
treated patients
DLX remitters and DLX nonremitters demonstrated different
trajectories in most of the HAM-D17 items (MMRM with actual
visit scores; Fig. 1A). For some items, lower scores for remitters,
compared to nonremitters, were observed even at baseline (e.g.
item 1 [depressed mood], item 7 [work and activities], and item 10
[anxiety: psychic]). For most items, the difference between re-
mitters and nonremitters increased over time. Note that the ran-
ges of scores is 0–2 for items 4–6, 12–14, 16, and 17;0–4 for all
other items.
There was a tendency for the greatest improvement by DLX
remitters to be in those items for which the mean baseline scores
were the highest. This observation is best exempliﬁed by items 1
(depressed mood) and 7 (work and activity). Two other items,
both with a baseline score greater than 1.5 (2 [feelings of guilt] and
10 [anxiety-psychic]) showed at least an improvement of 1.0.
Among items with a score range of 0–2, item 13 (somatic symp-
toms: general) had the highest mean baseline scores and the lar-
gest improvement over the 8-week period.
The treatment response trajectories for DLX remitters and
nonremitters on the HAM-D17 total and subscales are shown in
Fig. 1B. All subscales as well as the total score showed substantial
differences between remitters and nonremitters at baseline (re-
mitters had less severe symptoms), and these differences devel-
oped over time.
Fig. 2A presents comparisons of trajectories of depression
symptoms between DLX- and PLA-treated patients in remitters
and nonremitters for each of the items of the HAM-D17. A similar
trajectory of symptom changes was observed for the DLX remitters
and PLA remitters on virtually all items. Small separations be-
tween these trajectories were observed at baseline or other as-
sessment time points, but not at endpoint (e.g. items 1 [depressed
mood], 5 [insomnia: middle], 10 [anxiety: psychic], and 12 [so-
matic: gastrointestinal]). For nonremitters (DLX versus PLA), tra-
jectories were not as similar. On several items (notably items 1
[depressed mood], 2 [feelings of guilt], 3 [suicide], 7 [work and
activities], 8 [retardation], 10 [anxiety: psychic], and 15 [hy-
pochondriasis]), there was more improvement in the DLX non-
remitters, compared to the PLA nonremitters, at week 8 (Po .05
Table 1
Baseline demographics and disease characteristics.
Parameter DLXþPLA
(N¼2761)
DLX P-value PLA P-value P-value
DLX vs
PLAaTotal
(N¼1555)
Remitters
(n¼489)
Nonremitters
(n¼1066)
Total
(N¼1206)
Remitters
(n¼290)
Nonremitters
(n¼916)
Gender, n (%) .6663 .0795 .7338
Male 985 (35.7) 559 (35.9) 172 (35.2) 387 (36.3) 426 (35.3) 90 (31.0) 336 (36.7)
Female 1776 (64.3) 996 (64.1) 317 (64.8) 679 (63.7) 780 (64.7) 200 (69.0) 580 (63.3)
Race/ethnic ori-
gin, n (%)
.0094 .0262 .6887
Caucasian 2107 (76.3) 1175 (75.6) 345 (70.6) 830 (77.9) 932 (77.3) 214 (73.8) 718 (78.4)
African
American
287 (10.4) 163 (10.5) 60 (12.3) 103 (9.7) 124 (10.3) 27 (9.3) 97 (10.6)
Hispanic OR
Latino
309 (11.2) 183 (11.8) 74 (15.1) 109 (10.2) 126 (10.4) 44 (15.2) 82 (9.0)
Other 58 (2.1) 34 (2.2) 10 (2.0) 24 (2.3) 24 (2.0) 5 (1.7) 19 (2.1)
Age (years),
mean (SD)
46.2 (15.9) 46.9 (16.1) 47.1 (15.9) 46.9 (16.2) .7695 45.3 (15.5) 44.0 (16.4) 45.7 (15.2) .0971 .0078
HAM-D17 total
score, mean
(SD)
20.3 (5.2) 20.5 (5.3) 18.9 (5.6) 21.2 (4.9) o .0001 20.2 (5.1) 17.9 (5.6) 20.9 (4.7) o .0001 .1458
Current MDD
episode, n (%)
.9609 .4987 .0794
First 511 (18.5) 284 (18.3) 90 (18.4) 194 (18.2) 227 (18.8) 49 (16.9) 178 (19.4)
Other 2015 (73.0) 1206 (77.6) 384 (78.5) 822 (77.1) 809 (67.1) 192 (66.2) 617 (67.4)
Missing 235 (8.5) 65 (4.2) 15 (3.1) 50 (4.7) 170 (14.1) 49 (16.9) 121 (13.2)
Age at ﬁrst epi-
sode (years),
mean (SD)
28.8 (14.2) 29.1 (13.8) 28.4 (13.6) 29.4 (13.9) .3455 28.5 (14.6) 27.6 (14.1) 28.8 (14.7) .3675 .4191
Abbreviations: DLX¼duloxetine; HAM-D17¼17-item Hamilton Depression Rating Scale; MDD¼major depressive disorder; N¼total number of patients; n¼number of
affected patients; PLA¼placebo; SD¼standard deviation.
a Compares “total” columns.
Table 2
Patient disposition.
DLX P-value PLA P-value P-value DLX
vs PLAa
Total
(N¼1555)
Remitters
(n¼489)
Nonremitters
(n¼1066)
Total
(N¼1206)
Remitters
(n¼290)
Nonremitters
(n¼916)
Early discontinuation, n
(%)b
368 (23.7) 50 (10.2) 318 (29.8) o .0001 338 (28.0) 35 (12.1) 303 (33.1) o .0001 .0092
Reasons for early dis-
continuations, n (%)
Adverse events 126 (8.1) 16 (3.3) 110 (10.3) o .0001 54 (4.5) 5 (1.7) 49 (5.3) .0014 .0014
Patient decision 82 (5.3) 11 (2.2) 71 (6.7) o .0001 71 (5.9) 11 (3.8) 60 (6.6) .0125 .3145
Lost to follow-up 62 (4.0) 14 (2.9) 48 (4.5) .0215 58 (4.8) 9 (3.1) 49 (5.3) .0236 .1893
Lack of efﬁcacy 50 (3.2) 1 (.2) 49 (4.6) o .0001 119 (9.9) 1 (.3) 118 (12.9) o .0001 o .0001
Protocol violation 35 (2.3) 6 (1.2) 29 (2.7) .0162 22 (1.8) 8 (2.8) 14 (1.5) .4782 .5828
Physician decision 9 (.6) 2 (.4) 7 (.7) .3605 9 (.7) 1 (.3) 8 (.9) .2305 .5069
Sponsor decision 2 (.1) 0 2 (.2) .2789 3 (.2) 0 3 (.3) .2643 .4220
Death 1 (o .1) 0 1 (o .1) .4437 1 (o .1) 0 1 (.1) .5190 .8242
Other 1 (o .1) 0 1 (o .1) .4437 1 (o .1) 0 1 (.1) .5190 .8242
Abbreviations: DLX¼duloxetine; N¼total number of patients; n¼number of affected patients; PLA¼placebo.
a Compares “total” columns.
b A completer was deﬁned as a patient who completed the acute phase of the original study or at least continued beyond week 8 of data collection. Otherwise, the
threshold for completion was the last date of HAM-D17 measurement assigned to week 8 or, if this was not available, day 70 postbaseline.
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Comparisons of trajectories of DLX remitters and DLX non-
remitters on total score and subscale scores of the HAM-D17 are
shown in Fig. 2B. As with the individual items (Fig. 2A), DLX re-
mitters and PLA remitters showed similar trajectories for total
HAM-D17 scores and all subscale scores. DLX nonremitters
showed better improvement than nonremitters for the HAM-D17
total score and all subscale scores (week 8, Po .05), except the
Sleep subscale.
As a sensitivity analysis, the same analysis of trajectories of
HAM-D items was applied to a more restricted population with acomplete dataset (no missing data), for which imputation by LOCF
was not needed. The results were almost identical to those shown
in Fig. 1A and Fig. 2A (data not shown). Hence, the trajectory data
based on the LOCF method we originally used for the deﬁnition of
remitters and nonremitters can be regarded fairly reasonable and
robust.
3.3. Grouping of trajectories
To better characterize the improvement in responses on HAM-
D17 items of DLX-treated remitters, we assessed if there were
groups of HAM-D17 items based on their trajectories.
Fig. 1. Trajectories of depression symptoms in remitters and nonremitters treated with DLX. (A) Individual HAM-D17 items. The ranges of scores is 0-2 for items 4–6, 12–14,
16, and 17; 0-4 for all other items. (B) HAM-D17 total and subscales. The maximum possible value for the HAM-D17 total score is 52; the maximum possible values for the
subscale scores are as follows: Bech, 22; Maier, 24; Retardation, 14; Sleep, 6; and Anxiety/somatization, 18. nPo .05, nnPo .01, nnnPo .001. Abbreviations: DLX¼duloxetine;
gastro.¼gastro-intestinal; HAM-D17¼17-item Hamilton Scale of Depression.
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and Dienel (2002). A factor analysis (Table 3) identiﬁed 5-6 groups
at each assessment point (weeks 1, 2, 4, and 8). Some items werecategorized in the same group with respect to the highest loading
at all time points, and these items were designated as a trajectory
group. We found 3 such trajectory groups (A, B, and C). Group A
Fig. 2. Comparison of trajectories of depression symptoms between DLX- and PLA-treated patients in remitters and nonremitters. (A) Individual HAM-D17 items. The ranges
of scores is 0-2 for items 4–6, 12–14, 16, and 17; 0-4 for all other items. (B) HAM-D17 total and subscales. The maximum value for the HAM-D17 total score is 52; the
maximum values for the subscale scores are as follows: Bech, 22; Maier, 24; Retardation, 14; Sleep, 6; and Anxiety/somatization, 18. #DLX remitters versus PLA remitters; †DLX
nonremitters versus PLA nonremitters (1, 2 and 3 symbols refers to Po .05, Po .01, and Po .001, respectively). Abbreviations: DLX¼duloxetine; gastro.¼gastro-intestinal;
HAM-D17¼17-item Hamilton Scale of Depression; PLA¼placebo.
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Table 3
Grouping of HAM-D17 items’ trajectories in remitters treated with DLX based on
factor analysis.
HAM-D17 items Primary factor at each week Trajectory
group
Week 1 Week 2 Week 4 Week 8
1 Depressed mood 1 1 1 1
2 Feelings of guilt 1 1 1 5
3 Suicide 1 1 4 5
4 Insomnia early 3 3 2 2 A
5 Insomnia middle 3 3 2 2 A
6 Insomnia late 3 3 2 2 A
7 Work and
activities
2 1 1 1 B
8 Retardation 2 1 1 1 B
9 Agitation 6 5 5 4
10 Anxiety (psychic) 1 1 1 4
11 Anxiety (somatic) 5 4 6 4
12 Somatic (gastro-
intestinal)
4 2 3 3 C
13 Somatic (general) 2 1 1 1 B
14 Genital symptoms 2 2 6 1
15 Hypochondriasis 5 4 4 4
16 Weight loss 4 2 3 3 C
17 Insight 6 5 6(-) 6
Note: Factor analysis with Varimax rotation was conducted to characterize HAM-
D17 individual items at each week. A trajectory group was deﬁned as a group of
HAM-D17 items which showed the same pattern of primary factor at all time
points. A minus sign (-) indicates an opposite vector sign in that particular factor
and implies a change in score in the direction opposite to the other items with the
same primary factor. At week 4, items 11, 14 and 17 were characterized with factor
6. However, the change in score for item 17 was opposite to items 11 and 14.
Abbreviations: DLX¼duloxetine; HAM-D17¼17-item Hamilton Scale of Depression.
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and item 6 (insomnia: late). Group B comprised item 7 (work and
activities), item 8 (retardation), and item 13 (somatic symptoms:
general). Notably, item 1 (depressed mood) was also similar to
Group B, except at week 1. Group C comprised item 12 (somatic
symptoms: gastrointestinal) and item 16 (weight loss).
In PLA remitters (Supplementary Table 2), we found only
2 trajectory groups, and these were slightly different from those
found in the DLX remitters. Group A in the remitters was similar to
the DLX remitters, except only 2 of 3 insomnia items fell into the
same group (item 5 [insomnia: middle] and item 6 [insomnia:
late]). Group B included items 1 (depressed mood), 7 (work and
activities), and 10 (anxiety: psychic). Loading data for DLX- and
PLA-treated patients can be found in Supplementary Table 3.
3.4. Predictor analysis: prediction of remission using early im-
provement in individual HAM-D17 items
We used both a stepwise algorithm and a backward algorithm
to analyse the prediction of remission (at week 8) by early im-
provement of each HAM-D17. Because the 2 algorithms produced
the same results, here we show only results from the stepwise
algorithm (Fig. 3). In the DLX group, similar but different 6 items
were identiﬁed for weeks 1 and 2, as signiﬁcant contributors in
predicting remission at week 8 (LOCF). At week 1, item 1 (de-
pressed mood, odds ratio [OR]¼1.19, 95% conﬁdence interval
[CI]¼1.03–1.38), item 2 (feelings of guilt, OR¼1.23, 95% CI¼1.07–
1.42), item 5 (insomnia middle, OR¼1.17, 95% CI¼1.02–1.34), item
7 (work and activity, OR¼1.25, 95% CI¼1.08–1.45), item 8 (re-
tardation, OR¼1.36, 95% CI¼1.14–1.62), and item 16 (weight loss,
OR¼1.28, 95% CI¼1.07–1.53) were identiﬁed. At week 2, item 1
(depressed mood, OR¼1.28, 95% CI¼1.11–1.46), item 2 (feelings of
guilt, OR¼1.25, 95% CI¼1.08–1.44), item 5 (insomnia middle,
OR¼1.26, 95% CI¼1.10–1.44), item 7 (work and activity, OR¼1.24,95% CI¼1.08–1.44), item 9 (agitation, OR¼1.17, 95% CI¼1.01–1.35),
and item 13 (somatic symptoms: general, OR¼1.25, 95% CI¼1.05–
1.48) were identiﬁed.
In the PLA group, 3 and 4 items were identiﬁed as signiﬁcant
contributors for week 1 and 2, respectively. Those items, except
item 4 (insomnia early), are identiﬁed in the DLX group as well. At
week 1, item 1 (depressed mood, OR¼1.26, 95% CI¼1.06–1.50),
item 5 (insomnia middle, OR¼1.40, 95% CI¼1.17–1.67), and item 7
(work and activity, OR¼1.60, 95% CI¼1.33–1.92) were identiﬁed.
At week 2, item 1 (depressed mood, OR¼1.34, 95% CI¼1.14–1.56),
item 4 (insomnia early, OR¼1.24, 95% CI¼1.06–1.47), item 5 (in-
somnia middle, OR¼1.32, 95% CI¼1.11–1.57), and item 7 (work
and activity, OR¼1.38, 95% CI¼1.17–1.62) were identiﬁed.
In addition, to check the validity of the models selected by the
stepwise algorithm in providing ORs, we veriﬁed their predict-
ability on 4 logistics models using ROC curves and corresponding
AUC (Supplementary Fig. 1). For example, in the DLX group week
1 result, the selected model (items 1, 2, 5, 7, 8, and 16) has
AUC¼ .6557 (95% CI¼ .6255‒.6859) which was statistically sig-
niﬁcantly different from AUC¼ .5. (Note that AUC¼ .5 implies the
selected model is noninformative and AUC¼1 implies that model
prediction is perfect.) Six AUCs generated by individual item
(items 1, 2, 5, 7, 8, and 16) had a statistically signiﬁcant difference
from AUC¼ .5 but were smaller than the selected model. In this
way, all 4 models selected by the stepwise algorithm (equivalent
to backward algorithm results) were veriﬁed to be reasonable for
the outcome prediction.
We also analysed the prediction of remission (at week 8) using
early improvement of each HAM-D17 item, partly to compare with
the previous study by Sakurai et al. (2013) (Supplementary
Fig. 2A). For DLX, the majority of HAM-D17 items showed a sta-
tistically signiﬁcant positive association between early improve-
ment (week 1 or week 2) and remission at week 8. In contrast,
fewer HAM-D17 items demonstrated a statistically signiﬁcant re-
lationship with remission for the PLA group than for the DLX
group (Supplementary Fig. 2A). These results on individual items
demonstrated consistent trend with the stepwise algorithm result.
In both DLX- and PLA-treated patients, early improvement of
the HAM-D17 total score and all subscale scores was signiﬁcantly
associated with remission at week 8 (Supplementary Fig. 2B).
There were few marked differences between the DLX and PLA
groups at week 1 or week 2. However, at week 1, the Sleep sub-
scale was the most predictive of remission for the PLA group
(OR¼1.28, 95% CI¼1.17–1.39), but was the least predictive sub-
scale for the DLX group (OR¼1.15, 95% CI¼1.08–1.23).4. Discussion
4.1. Trajectory of symptom improvement in remitters and
nonremitters
In this report, we have demonstrated that response trajectories
of HAM-D17 items are different in remitters and nonremitters
treated with DLX. To our knowledge, this is the ﬁrst report on the
response trajectories of remitters and nonremitters using the
HAM-D as the assessment scale in patients with depression.
It is clinically important how remitters and nonremitters differ
early on in their responses to treatment for their depression. Early
recognition of clinical response (or lack of response) would allow
for earlier adjustment of dosage or change of pharmacotherapy to
optimize treatment for the patient. Our data suggest some items
show more improvement than others and that this improvement
is evident as early as 1 or 2 weeks after the start of treatment. The
largest improvement was shown in items 1 (depressed mood) and
7 (work and activities). These results are consistent with ﬁndings
Fig. 3. Predictor analysis of early improvement of each HAM-D17 item for remission in MDD patients treated with DLX or PLA, with stepwise algorithm. Note that odds ratios
are shown per 1-point change in the scale. Thus, the total likelihood of remission depends, in part, on the range of the scale. Error bars represent 95% conﬁdence intervals.
Abbreviations: DLX¼duloxetine; HAM-D17¼17-item Hamilton Scale of Depression; MDD¼major depressive disorder; PLA¼placebo.
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ment, as assessed by QIDS–SR16 and QIDS-C16, showed major
changes in 14-week treatment. Thus, those core symptoms could
be important indicators to evaluate the treatment outcomes.
Trajectory-based analysis has been used for research of de-
pression treatment and outcomes. For example, depressed mood
and positive well-being improve in parallel, while physical
symptoms and work functioning follow a different pattern of im-
provement (Aikens et al., 2008). It has been demonstrated with
trajectory-based statistical analysis and growth mixture modeling
that DLX-treated patients with MDD follow 1 of 2 trajectories:
responders and non-responders (Gueorguieva et al., 2011). How-
ever, these studies did not focus on the differences in trajectories
among different depression symptoms. Recently, Sakurai et al.
(2013) demonstrated that depression symptoms show improve-
ment with citalopram treatment over time in both remitters and
nonremitters, as measured using the QIDS–SR16 and QIDS-C16.
Our data support that ﬁnding, though with a different treatment
(DLX) and using a different scale (the HAM-D17) to measure
symptom improvement.
It has not been well investigated if remitters treated with an-
tidepressants follow the same trajectory as remitters treated with
PLA. The present report addressed this question by comparing
trajectories of DLX- and PLA-treated patients, and showed that
remitters from both treatment groups follow similar trajectories of
symptom improvement. A larger percentage of DLX-treated pa-
tients experience remission compared with PLA-treated patients
as shown in this study as well as in previous reports (Detke et al.,
2002; Goldstein et al., 2002; Nemeroff et al., 2002). Therefore,
more patients reach remission with DLX treatment, though re-
mitters' trajectories are similar with DLX and PLA treatment. One
possible explanation for this similarity in remitters is that the
speed of the recovery process from depression may be limited
biologically, and DLX may not accelerate the process any further. In
relation to this possibility, it has been reported that the time to
onset of improvement in responders is virtually the same for an-
tidepressants (imipramine and moclobemide) and placebo, and
resilience is proposed as an underlying mechanism (Stassen et al.,
2007). DLX may facilitate initiation of the remission process, while
not affecting the speed of the remission process.
When DLX nonremitters and PLA nonremitters are compared,DLX showed greater improvement in some items. Thus, even pa-
tients who do not appear to be following a trajectory leading to
remission may beneﬁt from DLX treatment. This effect was most
strongly demonstrated in item 1 (depressed mood), a core symp-
tom of depression, and item 10 (anxiety: psychic). Improvement in
symptoms of anxiety, even in nonremitters, makes sense given
DLX’s demonstrated efﬁcacy in the treatment of anxiety (Norman
and Olver, 2008).
4.2. Grouping of trajectories
The results of the grouping by factor analysis have face validity
and make intuitive sense. Group A, for example, comprises the
3 sleep-related items, which would be expected to improve to-
gether. Group C is composed of item 12 (somatic [gastrointestinal]
symptoms and item 16 (weight loss), which also would be ex-
pected to be related. One might also expect that item 7 (work and
activities), item 8 (psychomotor retardation), and item 13 (somatic
symptoms: general) would improve together (Group B). These
3 items are joined by item 1 (depressed mood), ignoring week 1.
Group B is composed of items closely related to the core symptoms
of depression. The data suggest that these HAM-D17 items change
in parallel for patients who will eventually be classiﬁed as
remitters.
Grouping of depression symptoms using the HAM-D has been
attempted previously (Cleary and Guy, 1977; Kasper and Dienel,
2002). Those studies used HAM-D scores at baseline or endpoint
for the analysis, in a static manner. In the present study, we used
HAM-D17 score change from baseline to assess whether symp-
toms can be grouped in terms of improvement pattern (in re-
mitters) over time. Despite this methodological difference, those
previous reports and our results highlight a close relationship
between gastrointestinal symptoms and loss of weight, as well as
the relationship among the 3 insomnia items.
4.3. Predictor analysis of early improvement for remission
Prediction of depression treatment outcome based on early
symptom change has been extensively investigated. Regarding
DLX, early symptom change, evaluated by HAM-D17 subscale
scores, has been shown to predict remission (Katz et al., 2009).
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HAM-D17 item may predict the outcome. Early prediction was
attempted in a study using the QIDS-SR16 and QIDS-C16 to eval-
uate depression symptom improvement with citalopram (Sakurai
et al., 2013). They found some core symptoms (sad mood, negative
self-view, feeling slowed down, low energy, and restlessness) to be
associated with remission. Our results are consistent with the
Sakurai et al. ﬁndings, suggesting the importance of core symp-
toms in early the prediction of treatment outcome with DLX as
well. Moreover, the clinical trials used in this analysis employed
the HAM-D17, which is more commonly used in clinical trials of
MDD than QIDS-SR16 and QIDS-C16.
Both the stepwise algorithm and the backward algorithm for
model selection lead to the same models of logistic analysis. The
selected models were further veriﬁed by ROC curves. Our ﬁnding
highlighted a few key items in the prediction of remission when
treated with DLX. Notably, items 1 (depressed mood), 2 (feelings of
guilt), 5 (insomnia middle), and 7 (work and activities) are con-
sistently signiﬁcant factors at both week 1 and 2. There were other
items identiﬁed as signiﬁcant factors: items 8 (retardation) and 16
(weight loss) at week 1, and items 9 (agitation) and 13 (somatic
symptoms: general) at week 2. Those items are worthy of atten-
tion as well in assessing recovery. Notably, 6 of those identiﬁed
items (items 1, 2, 7, 8, 9, and 13) are included in the Bech subscale
(Bech et al., 1975) or Maier subscale (Maier and Philipp, 1985),
representing core symptoms of MDD. With the exception of item 9
(anxiety), these items also showed similar patterns of trajectories,
as seen in Table 3. Thus, these data suggest that prediction of re-
mission could be improved by focusing on the core symptoms of
MDD.
In contrast, we identiﬁed fewer items in our analysis of the PLA
group. Most identiﬁed items were also signiﬁcant in the DLX
group: items 1 (depressed mood), 5 (insomnia middle), and 7
(work and activities), supporting the importance of those items in
depression treatment. Notably, the comparison with PLA manifests
the involvement of item 2 (feelings of guilt) in the DLX group. The
result that item 2 (feelings of guilt) is a signiﬁcant predictor in the
DLX group but not in the PLA group suggests DLX has an effect on
item 2 (feelings of guilt) relevant to remission.
The ROC curve analysis supported those results from a different
perspective. There was a consistent tendency that AUCs at week
1 were less signiﬁcantly informative than those at week 2. For
example, the DLX week 1 AUC (.6557 [95% CI¼ .6255–.6859]) was
smaller than the DLX week 2 AUC (.6865 [95% CI¼ .6563–.7167]). It
is a reasonable result because week 2 was closer to the endpoint
than week 1. Therefore, it should be more predictable. Never-
theless, it should be noted that the data of individual items'
change at week 1 contains statistically signiﬁcant information for
prediction.
We also conducted predictor analyses for individual items. The
results were similar to those from the stepwise algorithm. For
example, for DLX week 1, 4 of the 6 items selected by the stepwise
algorithm (Fig. 3) had the largest ORs estimated by individual lo-
gistic regressions (item 8¼1.58, item 7¼1.53, item 1¼1.46, item
2¼1.43; Supplementary Fig. 2). Similar results were found for DLX
week 2 (5 out of 6 items overlapped), for PLA week 1 (3 out of
3 items overlapped), and for PLA week 2 (3 out of 4 items
overlapped).
The HAM-D17 total score and subscale scores were all sig-
niﬁcantly predictive of remission. Of these, the Retardation sub-
scale showed the highest OR, suggesting that symptoms related to
this subscale, such as low energy, are worth paying close attention
to when treating depression with DLX. This result is also con-
sistent with the result of analysis for each item at week 1 by
stepwise algorithm. One may notice that the most of the ORs for
the subscales are smaller than those of the individual items. This islargely because the OR is shown per 1-point change in each scale.
Together with trajectory data, those prediction analyses sug-
gest that most of the symptoms show better improvement over
time in remitters compared with nonremitters, and particularly
some core symptoms are more worthy of attention in assessing
possibility of remission.
4.4. Limitations
There are several limitations which should be considered when
evaluating the results of the present analyses. First, remission was
deﬁned by HAM-D17 total score at week 8 only. Trajectories and
early prediction for remission after week 8 are possibly different.
Note that remission rate increases over time, even after week 8
(Detke et al., 2004). Therefore, the nonremitter group in our
analyses may contain patients who would have remitted if treat-
ment had been continued. Second, differences in the assessment
time points and frequency of HAM-D17 assessments in the in-
cluded studies made it difﬁcult to evaluate all patients in the same
manner at each of the included time points (e.g. weeks 1, 2, 4, and
8). Third, the generalizability of our results to a clinical practice
setting may be limited by the inclusion and exclusion criteria that
are inherent to clinical trials. Fourth, the present analyses are
based on patients whose DLX dose was Z40 and r60 mg/day.
Therefore, the results shown in this study may not be applicable to
DLX doses outside of that range. These data (using treatment with
DLX) may not easily generalize to other antidepressants, though
the similarity between the DLX and results suggests there may be
commonalities with other antidepressants.
Fifth, we used MMRM as a valid method for our dataset even
though normality assumption was not fully met. However, the
MMRM can provide intuitive visual comparison by treating in-
dividual items as continuous variable, rather categorical variables.
Moreover, other statistical methods such as nonparametric
methods (smoothing) would not be applicable due to sparse
timepoints (weeks 0, 1, 2, 4, and 8) in our case.
Finally, because this was a post hoc analysis and no adjustments
for multiple comparisons were made, the powering of the study
should be considered when evaluating the outcomes of the
variables.
4.5. Conclusions
Our analyses of trajectories in remitters and nonremitters, and
the predictions of remission by individual HAM-D items, highlight
the relevance of core depressive symptoms for remission in MDD
patients treated with DLX. The results presented here suggest that
early, substantial improvements in some core symptoms of de-
pression may prove useful in guiding clinical decisions during the
ﬁrst few weeks of treatment of depression with DLX.Conﬂicts of interest
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